| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Natural anti-inflammatory agent
Quercetagitrin exerts anti-inflammatory effects by targeting neutrophil activation-related processes, including degranulation (mediated by lysosomal enzyme release) and arachidonic acid release (mediated by phospholipase A2-related pathways)[2] |
|---|---|
| ln Vitro |
In this study, researchers assessed the effects of 24 flavonoid derivatives, reported as anti-inflammatory, on lysosomal enzyme secretion and arachidonic acid release in rat neutrophils. Amentoflavone, quercetagetin-7-O-glucoside, apigenin, fisetin, kaempferol, luteolin and quercetin were the most potent inhibitors of beta-glucuronidase and lysozyme release. The first compound was also able to inhibit basal release. These flavonoids besides chrysin and to a reduced extent, naringenin, significantly inhibited arachidonic acid release from membranes. A correlation between degranulation and arachidonic acid release was found for this series of compounds. Structure-activity relationships and implications for the anti-inflammatory effects of these flavonoids were discussed.
In fMLP (N-formyl-methionyl-leucyl-phenylalanine)-stimulated rat neutrophils, Quercetagitrin inhibited degranulation in a dose-dependent manner: at concentrations of 10 μM, 30 μM, and 100 μM, it reduced the release of β-glucuronidase (a lysosomal enzyme marker for degranulation) by ~15%, ~30%, and ~50%, respectively, compared to untreated stimulated controls[2] Quercetagitrin also suppressed arachidonic acid release from fMLP-stimulated rat neutrophils in a dose-dependent way: 30 μM and 100 μM Quercetagitrin decreased arachidonic acid release by ~25% and ~40%, respectively, relative to stimulated controls[2] At the tested concentrations (up to 100 μM), Quercetagitrin had no significant cytotoxic effect on rat neutrophils, as confirmed by trypan blue exclusion assay[2] |
| Enzyme Assay |
β-glucuronidase activity assay (for degranulation detection): Rat neutrophils were treated with Quercetagitrin (10-100 μM) for 10 min, then stimulated with fMLP for 30 min; the reaction was terminated by centrifugation, and the supernatant was collected. The supernatant was mixed with β-glucuronidase substrate (4-methylumbelliferyl-β-D-glucuronide) in citrate buffer (pH 4.5), incubated at 37°C for 60 min, and the reaction was stopped with glycine-NaOH buffer (pH 10.3). Fluorescence intensity was measured at excitation 365 nm and emission 450 nm to quantify β-glucuronidase release[2]
Arachidonic acid release assay: Rat neutrophils were pre-labeled with [3H]-arachidonic acid for 2 h, washed to remove unincorporated label, then treated with Quercetagitrin (10-100 μM) for 10 min and stimulated with fMLP for 30 min. The reaction was stopped by adding ice-cold trichloroacetic acid, and the mixture was centrifuged. The supernatant was extracted with diethyl ether, and the radioactivity of the ether phase was measured by liquid scintillation counting to determine [3H]-arachidonic acid release[2] |
| Cell Assay |
Rat neutrophil isolation and treatment assay: Neutrophils were isolated from rat peritoneal exudates (induced by casein injection 16 h prior). The exudate was centrifuged, and the cell pellet was resuspended in Hank's balanced salt solution (HBSS). Neutrophils were purified by density gradient centrifugation (using Ficoll-Hypaque), and cell purity (>95%) was confirmed by Wright-Giemsa staining. Purified neutrophils were resuspended in HBSS containing calcium and magnesium, treated with Quercetagitrin (10-100 μM) for 10 min, then stimulated with fMLP (100 nM) to induce degranulation and arachidonic acid release[2]
Cytotoxicity assay (trypan blue exclusion): After Quercetagitrin treatment (10-100 μM) for 40 min (10 min pretreatment + 30 min fMLP stimulation), trypan blue solution (0.4%) was added to the neutrophil suspension at a 1:1 ratio. The number of viable (trypan blue-negative) and dead (trypan blue-positive) cells was counted under a light microscope to calculate cell viability[2] |
| References |
|
| Additional Infomation |
Quercetin is a flavonoid glycoside. It has been reported that quercetin exists in Clibadium surinamense, Achillea biebersteinii, and other organisms with relevant data. Quercetin is a flavonoid glycoside, specifically a 7-O-β-D-glucopyranoside of quercetin (a flavonol derivative); this study is the first to isolate this compound from plants of the Asteraceae family (e.g., marigolds) [1]. The separation process of quercetin: the dried plant material was extracted with hot ethanol; the ethanol extract was concentrated under reduced pressure and then extracted with ethyl acetate and water. The ethyl acetate extract was separated by column chromatography (using alumina as an adsorbent) and eluted with a benzene-ethyl acetate mixture with gradually increasing polarity. The eluent was analyzed by paper chromatography and recrystallized from methanol to obtain yellow crystalline solid quercetin [1]. The anti-inflammatory mechanism of quercetin is related to its ability to inhibit neutrophil activation: by reducing degranulation (lysosomal enzyme release) and arachidonic acid metabolism (a precursor to pro-inflammatory eicosate), it reduces the production and release of inflammatory mediators[2].
|
| Molecular Formula |
C21H20O13
|
|---|---|
| Molecular Weight |
480.3757
|
| Exact Mass |
480.09
|
| CAS # |
548-75-4
|
| PubChem CID |
5320826
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.883g/cm3
|
| Boiling Point |
908ºC at 760mmHg
|
| Melting Point |
236-238℃
|
| Flash Point |
318.3ºC
|
| Index of Refraction |
1.799
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
789
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O)O
|
| InChi Key |
IDTDRZPBDLMCLB-HSOQPIRZSA-N
|
| InChi Code |
InChI=1S/C21H20O13/c22-5-11-14(26)17(29)19(31)21(34-11)33-10-4-9-12(15(27)13(10)25)16(28)18(30)20(32-9)6-1-2-7(23)8(24)3-6/h1-4,11,14,17,19,21-27,29-31H,5H2/t11-,14-,17+,19-,21-/m1/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-3,5,6-trihydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| Synonyms |
Quercetagitrin; Quercetagetin-7-O-glucoside; 548-75-4; 4DX1W79Z8Y; 2-(3,4-dihydroxyphenyl)-3,5,6-trihydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Quercetagetin 7-O-glucoside; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-3,5,6-trihydroxy-; Quercetagetin 7-glucoside;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~260.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0817 mL | 10.4084 mL | 20.8169 mL | |
| 5 mM | 0.4163 mL | 2.0817 mL | 4.1634 mL | |
| 10 mM | 0.2082 mL | 1.0408 mL | 2.0817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
